Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies
- PMID: 11457514
- DOI: 10.1016/s0196-9781(01)00445-4
Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies
Abstract
Insights into the molecular basis of binding of the peptide hormone, cholecystokinin, to its G protein-coupled receptor is of substantial interest and may contribute to the successful production and refinement of receptor-active drugs. A number of methodological approaches provide complementary data to contribute to these insights. These include receptor mutagenesis, ligand structure-activity data, conformational analysis of ligand and receptor fragments, and photoaffinity labeling. In this work, we compare and contrast each of these methods and provide our current view of the cumulative impact of the current data on molecular conformational models of the agonist-occupied type A cholecystokinin receptor. These support the key roles played by extracellular loop and tail regions of this receptor for binding its natural peptide ligand.
Similar articles
-
Insights into the molecular basis of ligand binding by the cholecystokinin receptor.Pancreatology. 2001;1(4):336-42. doi: 10.1159/000055832. Pancreatology. 2001. PMID: 12120212 Review.
-
Elucidation of the molecular basis of cholecystokinin Peptide docking to its receptor using site-specific intrinsic photoaffinity labeling and molecular modeling.Biochemistry. 2009 Jun 16;48(23):5303-12. doi: 10.1021/bi9004705. Biochemistry. 2009. PMID: 19441839 Free PMC article.
-
Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.Mol Pharmacol. 2002 May;61(5):1041-52. doi: 10.1124/mol.61.5.1041. Mol Pharmacol. 2002. PMID: 11961122
-
Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.Mol Pharmacol. 2004 Sep;66(3):545-52. doi: 10.1124/mol.104.001396. Mol Pharmacol. 2004. PMID: 15322246
-
Molecular basis of agonist binding to the type A cholecystokinin receptor.Pharmacol Toxicol. 2002 Dec;91(6):282-5. doi: 10.1034/j.1600-0773.2002.910603.x. Pharmacol Toxicol. 2002. PMID: 12688369 Review.
Cited by
-
Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor.Br J Pharmacol. 2006 Apr;147(8):951-8. doi: 10.1038/sj.bjp.0706690. Br J Pharmacol. 2006. PMID: 16491099 Free PMC article.
-
Selective activation by photodynamic action of cholecystokinin receptor in the freshly isolated rat pancreatic acini.Br J Pharmacol. 2003 Jun;139(4):872-80. doi: 10.1038/sj.bjp.0705295. Br J Pharmacol. 2003. PMID: 12813011 Free PMC article.
-
Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.J Med Chem. 2006 Feb 9;49(3):850-63. doi: 10.1021/jm049072h. J Med Chem. 2006. PMID: 16451051 Free PMC article.
-
The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors.Annu Rev Biophys Biomol Struct. 2003;32:375-97. doi: 10.1146/annurev.biophys.32.110601.142520. Epub 2003 Feb 5. Annu Rev Biophys Biomol Struct. 2003. PMID: 12574068 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources